Chronic Refractory Gout Market, By Therapy Class, By Route of Administration, By Disease Burden, By Comorbidity Profile, By Care Setting, By Distribution Channel, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

Description

Chronic refractory gout market size was valued at US$ 1,804.25 Million in 2024, expanding at a CAGR of 10.23% from 2025 to 2032.

Chronic refractory gout is a severe form of gout in which patients do not respond adequately to standard urate-lowering therapies or cannot tolerate them. It is characterized by persistently high uric acid levels, frequent painful flares, and tophi formation that can damage joints and surrounding tissues. This condition often requires advanced treatments, such as uricase-based therapies or biologics, along with comprehensive management of comorbidities to reduce complications and improve quality of life.

Chronic Refractory Gout Market- Market Dynamics

Increasing burden of gouts across the globe to propel market demand

The rising global burden of gout is driving demand for advanced treatment options. In 2020, an estimated 55.8 million people worldwide were living with gout. Obesity and kidney dysfunction are major contributors to disability from the disease, with high body mass index accounting for 34.3% of years lived with disability (YLDs) due to gout, and kidney dysfunction contributing 11.8%. However, underdiagnosis of these comorbidities often delays appropriate treatment.

In the United States, the Centers for Disease Control and Prevention (CDC) reports that more than 1 in 7 adults have chronic kidney disease. On the positive side, lifestyle interventions targeting obesity can significantly reduce gout severity and progression. Additionally, improving chronic kidney disease (CKD) detection in gout patients could enhance treatment outcomes and help address one of the key underlying drivers of refractory cases.

Chronic Refractory Gout Market- Segmentation Analysis:

The Global Chronic Refractory Gout Market is segmented on the basis of Therapy Class, Route of Administration, Disease Burden, Comorbidity Profile, Propulsion, Distribution Channel, and Region.

The market is divided into four categories based on Therapy Class: uricase therapies, IL-1 inhibitors, adjunct anti-inflammatories, and next-generation small molecules. The uricase therapies segment is expected to hold the major market share during the forecast period. This dominance is driven by their unique ability to rapidly and effectively lower serum uric acid levels in patients unresponsive to conventional treatments.

The market is divided into two categories based on Comorbidity Profile: renal impairment and cardiovascular/metabolic conditions. Among these, the renal impairment segment is expected to capture the major market share. Chronic kidney disease is a frequent complication in gout patients, limiting the use of traditional urate-lowering drugs and creating higher reliance on advanced therapies like uricase-based treatments. Renal impairment poses the greatest therapeutic challenge, driving stronger demand for specialized and effective treatment options in this patient group.

Chronic Refractory Gout Market- Geographical Insights

North America cancer biopsy market dominated the global market, and a similar trend is observed in the chronic refractory gout segment due to high disease burden and strong healthcare infrastructure. According to the U.S. Centers for Disease Control and Prevention (CDC), nearly 9.2 million adults in the United States suffer from gout, representing about 3.9% of the adult population.

A significant proportion of these cases develop into chronic and treatment-resistant forms, driving the demand for advanced therapies such as pegloticase. The U.S. Food and Drug Administration (FDA) has prioritized approvals of biologics and novel urate-lowering drugs to address unmet needs in refractory cases. In Europe, the prevalence is also notable, with the UK's National Health Service (NHS) reporting a sharp rise in gout-related hospital admissions over the past decade. Meanwhile, in Asia Pacific, Japan's Ministry of Health and Welfare identifies gout as a growing concern linked to lifestyle diseases, further expanding treatment demand.

Chronic Refractory Gout Market- Competitive Landscape:

Rising prevalence of uncontrolled gout cases is encouraging companies to refine treatment strategies. Competitors are focusing on developing biologics and uricase-based therapies with improved safety and longer durability of response. Many are exploring combination regimens with immunomodulators to reduce antibody formation and enhance effectiveness. Partnerships with research institutes, specialty clinics, and payers aim to expand patient access. In parallel, firms are investing in patient-support programs, infusion services, and digital monitoring tools to strengthen adherence and improve long-term treatment outcomes.

Recent Development:

In March 2025, Shanton Pharma announced positive Phase 2b results for SAP-001 in refractory gout patients, showing nearly 100% target achievement versus 10% on conventional therapy, with sustained effects, strong efficacy, and excellent safety across six months of treatment.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CHRONIC REFRACTORY GOUT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

LG Chem
Jiangsu Hengrui Pharmaceuticals
JW Group / Simcere
Selecta / Cartesian Therapeutics
Sobi (Swedish Orphan Biovitrum)
Teijin America
InventisBio
Arthrosi Therapeutics
Shanton Pharma
Atom Bioscience
Horizon Therapeutics / Amgen
Nippon Chemiphar
Protalix BioTherapeutics
Arrowhead Pharmaceuticals
Hinova Pharmaceuticals
TaiwanJ Pharmaceuticals
Cartesian Therapeutics
Amgen
Takeda Pharmaceutical Company
AstraZeneca
Others

GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY THERAPY CLASS- MARKET ANALYSIS, 2019 - 2032

Uricase Therapies
IL-1 inhibitors
Adjunct Anti-inflammatories
Next-generation Small Molecules

GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Intravenous
Subcutaneous
Oral

GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY DISEASE BURDEN- MARKET ANALYSIS, 2019 - 2032

Tophaceous CRG
Frequent Flares
Erosive/structural damage

GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY COMORBIDITY PROFILE- MARKET ANALYSIS, 2019 - 2032

Renal Impairment
Cardiovascular/Metabolic Conditions

GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY CARE SETTING- MARKET ANALYSIS, 2019 - 2032

Hospitals
Specialty Rheumatology Clinics
Infusion Centers

GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

Hospital Pharmacies
Specialty Pharmacies
Retail

GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV5677

1. Chronic Refractory Gout Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Chronic Refractory Gout Market Snippet by Therapy Class
- 2.1.2. Chronic Refractory Gout Market Snippet by Route of Administration
- 2.1.3. Chronic Refractory Gout Market Snippet by Disease Burden
- 2.1.4. Chronic Refractory Gout Market Snippet by Comorbidity Profile
- 2.1.5. Chronic Refractory Gout Market Snippet by Care Setting
- 2.1.6. Chronic Refractory Gout Market Snippet by Distribution Channel
- 2.1.7. Chronic Refractory Gout Market Snippet by Country
- 2.1.8. Chronic Refractory Gout Market Snippet by Region
2.2. Competitive Insights

3. Chronic Refractory Gout Key Market Trends

3.1. Chronic Refractory Gout Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Chronic Refractory Gout Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Chronic Refractory Gout Market Opportunities
3.4. Chronic Refractory Gout Market Future Trends

4. Chronic Refractory Gout Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Chronic Refractory Gout Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Chronic Refractory Gout Market Landscape

6.1. Chronic Refractory Gout Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Chronic Refractory Gout Market - By Therapy Class

7.1. Overview
- 7.1.1. Segment Share Analysis, By Therapy Class, 2023 & 2032 (%)
  - 7.1.1.1. Uricase Therapies
  - 7.1.1.2. IL-1 Inhibitors
  - 7.1.1.3. Adjunct anti-inflammatories
  - 7.1.1.4. Next-generation Small Molecules

8. Chronic Refractory Gout Market - By Route of Administration

8.1. Overview
- 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
- 8.1.2. Intravenous
- 8.1.3. Subcutaneous
- 8.1.4. Oral

Chronic Refractory Gout Market - By Disease Burden

8.2. Overview
- 8.2.1. Segment Share Analysis, By Disease Burden, 2023 & 2032 (%)
- 8.2.2. Tophaceous CRG
- 8.2.3. Frequent Flares
- 8.2.4. Erosive/Structural Damage

9. Chronic Refractory Gout Market - By Comorbidity Profile

9.1. Overview
- 9.1.1. Segment Share Analysis, By Comorbidity Profile, 2023 & 2032 (%)
- 9.1.2. Renal Impairment
- 9.1.3. Cardiovascular/Metabolic Conditions

10. Chronic Refractory Gout Market - By Care Setting

10.1. Overview
- 10.1.1. Segment Share Analysis, By Care Setting, 2023 & 2032 (%)
- 10.1.2. Hospitals
- 10.1.3. Specialty Rheumatology Clinics
- 10.1.4. Infusion Centers

11. Chronic Refractory Gout Market - By Distribution Channel

11.1. Overview
- 11.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
- 11.1.2. Hospital Pharmacies
- 11.1.3. Specialty Pharmacies
- 11.1.4. Retail

12. Chronic Refractory Gout Market- By Geography

12.1. Introduction
- 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
12.2. North America
- 12.2.1. Overview
- 12.2.2. Chronic Refractory Gout Key Manufacturers in North America
- 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.2.4. North America Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
- 12.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.2.6. North America Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
- 12.2.7. North America Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
- 12.2.8. North America Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
- 12.2.9. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.2.10. U.S.
  - 12.2.10.1. Overview
  - 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.2.10.3. U.S. Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.2.10.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.2.10.5. U.S. Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.2.10.6. U.S. Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.2.10.7. U.S. Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.2.10.8. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.2.10.9.
- 12.2.11. Canada
  - 12.2.11.1. Overview
  - 12.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.2.11.3. Canada Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.2.11.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.2.11.5. Canada Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.2.11.6. Canada Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.2.11.7. Canada Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.2.11.8. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.2.11.9.
12.3. Europe
- 12.3.1. Overview
- 12.3.2. Chronic Refractory Gout Key Manufacturers in Europe
- 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.3.4. Europe Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
- 12.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.6. Europe Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
- 12.3.7. Europe Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
- 12.3.8. Europe Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
- 12.3.9. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.10. Germany
  - 12.3.10.1. Overview
  - 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.10.3. Germany Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.3.10.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.10.5. Germany Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.3.10.6. Germany Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.3.10.7. Germany Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.3.10.8. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.11. Italy
  - 12.3.11.1. Overview
  - 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.11.3. Italy Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.3.11.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.11.5. Italy Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.3.11.6. Italy Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.3.11.7. Italy Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.3.11.8. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.12. United Kingdom
  - 12.3.12.1. Overview
  - 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.12.3. United Kingdom Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.3.12.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.12.5. United Kingdom Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.3.12.6. United Kingdom Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.3.12.7. United Kingdom Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.3.12.8. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.13. France
  - 12.3.13.1. Overview
  - 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.13.3. France Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.3.13.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.13.5. France Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.3.13.6. France Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.3.13.7. France Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.3.13.8. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.14. Russia
  - 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.14.2. Russia Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.3.14.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.14.4. Russia Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.3.14.5. Russia Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.3.14.6. Russia Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.3.14.7. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.15. Netherlands
  - 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.15.2. Netherlands Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.3.15.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.15.4. Netherlands Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.3.15.5. Netherlands Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.3.15.6. Netherlands Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.3.15.7. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.16. Sweden
  - 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.16.2. Sweden Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.3.16.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.16.4. Sweden Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.3.16.5. Sweden Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.3.16.6. Sweden Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.3.16.7. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.17. Poland
  - 12.3.17.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.17.2. Poland Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.3.17.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.17.4. Poland Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.3.17.5. Poland Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.3.17.6. Poland Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.3.17.7. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.18. Rest of Europe
  - 12.3.18.1. Overview
  - 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.18.3. Rest of the Europe Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.3.18.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.18.5. Rest of the Europe Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.3.18.6. Rest of the Europe Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.3.18.7. Rest of the Europe Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.3.18.8. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
- 12.4.1. Overview
- 12.4.2. Chronic Refractory Gout Key Manufacturers in Asia Pacific
- 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.4.4. Asia Pacific Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
- 12.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.6. Asia Pacific Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
- 12.4.7. Asia Pacific Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
- 12.4.8. Asia Pacific Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
- 12.4.9. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.10. India
  - 12.4.10.1. Overview
  - 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.10.3. India Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.4.10.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.10.5. India Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.4.10.6. India Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.4.10.7. India Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.4.10.8. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.11. China
  - 12.4.11.1. Overview
  - 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.11.3. China Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.4.11.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.11.5. China Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.4.11.6. China Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.4.11.7. China Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.4.11.8. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.12. Japan
  - 12.4.12.1. Overview
  - 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.12.3. Japan Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.4.12.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.12.5. Japan Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.4.12.6. Japan Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.4.12.7. Japan Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.4.12.8. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.13. South Korea
  - 12.4.13.1. Overview
  - 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.13.3. South Korea Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.4.13.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.13.5. South Korea Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.4.13.6. South Korea Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.4.13.7. South Korea Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.4.13.8. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.14. Australia
  - 12.4.14.1. Overview
  - 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.14.3. Australia Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.4.14.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.14.5. Australia Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.4.14.6. Australia Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.4.14.7. Australia Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.4.14.8. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.15. Thailand
  - 12.4.15.1. Overview
  - 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.15.3. Thailand Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.4.15.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.15.5. Thailand Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.4.15.6. Thailand Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.4.15.7. Thailand Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.4.15.8. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.16. Indonesia
  - 12.4.16.1. Overview
  - 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.16.3. Indonesia Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.4.16.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.16.5. Indonesia Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.4.16.6. Indonesia Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.4.16.7. Indonesia Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.4.16.8. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.17. Philippines
  - 12.4.17.1. Overview
  - 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.17.3. Philippines Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.4.17.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.17.5. Philippines Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.4.17.6. Philippines Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.4.17.7. Philippines Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.4.17.8. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.18. Rest of APAC
  - 12.4.18.1. Overview
  - 12.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.18.3. Rest of APAC Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.4.18.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.18.5. Rest of APAC Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.4.18.6. Rest of APAC Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.4.18.7. Rest of APAC Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.4.18.8. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.5. Latin America
- 12.5.1. Overview
- 12.5.2. Chronic Refractory Gout Key Manufacturers in Latin America
- 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.5.4. Latin America Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
- 12.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.6. Latin America Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
- 12.5.7. Latin America Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
- 12.5.8. Latin America Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
- 12.5.9. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.10. Brazil
  - 12.5.10.1. Overview
  - 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.10.3. Brazil Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.5.10.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.10.5. Brazil Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.5.10.6. Brazil Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.5.10.7. Brazil Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.5.10.8. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.11. Mexico
  - 12.5.11.1. Overview
  - 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.11.3. Mexico Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.5.11.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.11.5. Mexico Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.5.11.6. Mexico Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.5.11.7. Mexico Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.5.11.8. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.12. Argentina
  - 12.5.12.1. Overview
  - 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.12.3. Argentina Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.5.12.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.12.5. Argentina Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.5.12.6. Argentina Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.5.12.7. Argentina Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.5.12.8. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.13. Colombia
  - 12.5.13.1. Overview
  - 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.13.3. Colombia Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.5.13.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.13.5. Colombia Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.5.13.6. Colombia Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.5.13.7. Colombia Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.5.13.8. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.14. Rest of LATAM
  - 12.5.14.1. Overview
  - 12.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.14.3. Rest of LATAM Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.5.14.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.14.5. Rest of LATAM Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.5.14.6. Rest of LATAM Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.5.14.7. Rest of LATAM Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.5.14.8. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
- 12.6.1. Overview
- 12.6.2. Chronic Refractory Gout Key Manufacturers in Middle East and Africa
- 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.6.4. Middle East and Africa Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
- 12.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.6. Middle East and Africa Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
- 12.6.7. Middle East and Africa Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
- 12.6.8. Middle East and Africa Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
- 12.6.9. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.10. Saudi Arabia
  - 12.6.10.1. Overview
  - 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.10.3. Saudi Arabia Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.6.10.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.10.5. Saudi Arabia Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.6.10.6. Saudi Arabia Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.6.10.7. Saudi Arabia Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.6.10.8. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.11. United Arab Emirates
  - 12.6.11.1. Overview
  - 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.11.3. United Arab Emirates Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.6.11.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.11.5. United Arab Emirates Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.6.11.6. United Arab Emirates Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.6.11.7. United Arab Emirates Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.6.11.8. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.12. Israel
  - 12.6.12.1. Overview
  - 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.12.3. Israel Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.6.12.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.12.5. Israel Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.6.12.6. Israel Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.6.12.7. Israel Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.6.12.8. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.13. Turkey
  - 12.6.13.1. Overview
  - 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.13.3. Turkey Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.6.13.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.13.5. Turkey Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.6.13.6. Turkey Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.6.13.7. Turkey Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.6.13.8. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.14. Algeria
  - 12.6.14.1. Overview
  - 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.14.3. Algeria Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.6.14.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.14.5. Algeria Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.6.14.6. Algeria Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.6.14.7. Algeria Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.6.14.8. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.15. Egypt
  - 12.6.15.1. Overview
  - 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.15.3. Egypt Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.6.15.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.15.5. Egypt Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.6.15.6. Egypt Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.6.15.7. Egypt Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.6.15.8. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.16. Rest of MEA
  - 12.6.16.1. Overview
  - 12.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.16.3. Rest of MEA Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
  - 12.6.16.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.16.5. Rest of MEA Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
  - 12.6.16.6. Rest of MEA Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
  - 12.6.16.7. Rest of MEA Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
  - 12.6.16.8. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Chronic Refractory Gout Industry

13.1. Competitive Dashboard
- 13.1.1. Competitive Benchmarking
- 13.1.2. Competitive Positioning
13.2. Company Profiles
- 13.2.1. LG Chem
- 13.2.2. Jiangsu Hengrui Pharmaceuticals
- 13.2.3. JW Group / Simcere
- 13.2.4. Selecta / Cartesian Therapeutics
- 13.2.5. Sobi (Swedish Orphan Biovitrum)
- 13.2.6. Teijin America
- 13.2.7. InventisBio
- 13.2.8. Arthrosi Therapeutics
- 13.2.9. Shanton Pharma
- 13.2.10. Atom Bioscience
- 13.2.11. Horizon Therapeutics / Amgen
- 13.2.12. Nippon Chemiphar
- 13.2.13. Protalix BioTherapeutics
- 13.2.14. Arrowhead Pharmaceuticals
- 13.2.15. Hinova Pharmaceuticals
- 13.2.16. TaiwanJ Pharmaceuticals
- 13.2.17. Cartesian Therapeutics
- 13.2.18. Amgen
- 13.2.19. Takeda Pharmaceutical Company
- 13.2.20. AstraZeneca
- 13.2.21. Others

14. 360 Degree Analyst View

15. Appendix

15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us